Prasugrel Inappropriate Use in Patients Post-percutaneous coronary intervention (PCI). A Single Center Study

Abstract

Prasugrel is a thienopyridine that was approved by the US Food and Drug Administration in combination with aspirin for the reduction of thrombotic events as well as stent thrombosis in patients with acute coronary syndrome who undergo percutaneous coronary intervention. This retrospective study aims to assess the frequency of inappropriate use of prasugrel and to emphasize that prasugrel still needs more attention as inappropriate use may result in significant morbidity.